# A Study of Inhaled Ampion in Adults With Respiratory Distress Due to COVID-19

> **NCT04868890** · PHASE2 · TERMINATED · sponsor: **Ampio Pharmaceuticals. Inc.** · enrollment: 200 (actual)

## Conditions studied

- Covid19

## Interventions

- **BIOLOGICAL:** Ampion
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04868890
- **Lead sponsor:** Ampio Pharmaceuticals. Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-06-22
- **Primary completion:** 2022-02-16
- **Final completion:** 2022-04-13
- **Target enrollment:** 200 (ACTUAL)
- **Why stopped:** The AP-019 study was prematurely terminated by the sponsor after determining that insufficient events were occurring to analyze the primary endpoint.
- **Last updated:** 2022-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04868890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04868890, "A Study of Inhaled Ampion in Adults With Respiratory Distress Due to COVID-19". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04868890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*